PULMONARY GRANULOCYTE MARGINATION IS INCREASED IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE

被引：11

作者：

JONKER, ND ^{[1
]}

PETERS, AM ^{[1
]}

DEKASKI, MC ^{[1
]}

HODGSON, HJ ^{[1
]}

LAVENDER, JP ^{[1
]}

机构：

[1] HAMMERSMITH HOSP,DEPT DIAGNOST RADIOL,DU CANE RD,LONDON W12 0HS,ENGLAND

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1992年 / 13卷 / 11期

关键词：

D O I：

10.1097/00006231-199211000-00006

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The pulmonary granulocyte content of the lung was quantified in patients with inflammatory bowel disease (IBD) after injection of In-111-labelled granulocytes and compared with patient controls, who, on the basis of their negative white cell scans, were not considered to have active inflammation. The mean ratios of lung:liver count rates per pixel on the posterior gamma camera image in patient controls was 0.34 (S.D. 0.16, n = 8) at 1-1.5 h after injection of the cells, and 0.29 (S.D. 0.14, n = 18) at 2-4 h. This ratio was higher in patients with active IBD at both imaging times: 0.45 (0.13, n = 13, P > 0.05) and 0.44 (0.1, n = 19, P < 0.001). Patients with inactive IBD also had increased ratios at both imaging times: 0.6 (0.14, n = 7, P < 0.01) and 0. 54 (0.15, n = 12, P < 0. 001), respectively. In a further group of 12 patients with active IBD, there was no correlation between the lung:liver ratio and the severity of the IBD as assessed by whole-body ln-111 retention at 4-6 days after labelled cell injection. These patients were treated for 3 weeks with an oral, non-absorbable corticosteroid, after which there was a significant decrease in disease activity but no significant change in the lung:liver ratio. Inflammatory bowel disease appears to be associated with abnormal pulmonary granulocyte accumulation. It is not apparently related to disease activity but may be the result of an associated pulmonary abnormality.

引用

页码：806 / 810

页数：5

共 27 条

[21]

Kraft S.C., Earle R.H., Roesler M., Easterly J.R., Unexplained broncho-pulmonary disease with inflammatory bowel disease, Arch Int Med, 136, pp. 454-459, (1976)

[22]

Lecouffe P., Vendel H., Huglo D., Colombel J.-F., Wallaert B., Marchandise X., Pulmonary and intestinal permeabilities in Crohn's disease, Eur J Nucl Med, 16, (1990)

[23]

Eade O.E., Smith C.L., Alexander J.R., Whorwell P.J., Pulmonary function in patients with inflammatory bowel disease, Am J Gastroenterol, 73, pp. 154-156, (1980)

[24]

Isenberg J.I., Goldstein H., Korn A.R., Ozeran R.S., Rosen V., Pulmonary vasculitis—an uncommon complication of ulcerative colitis. New Engl, J Med, 279, pp. 1376-1377, (1968)

[25]

Forrest J., Shearman D.J., Pulmonary vasculitis and ulcerative colitis, Am J Dig Dis, 20, pp. 482-486, (1975)

[26]

Dew M.J., Thompson H., Allan R.N., The spectrum of hepatic dysfunction in inflammatory bowel disease, Q J Med, 48, pp. 113-135, (1979)

[27]

Saverymuttu S.H., Peters A.M., Keshavarzian A., Reavy H.J., Lavender J.P., The kinetics of 111-indium distribution following injection of 111-indium labelled autologous granulocytes in man, Br J Haematol, 61, pp. 675-685, (1985)

← 1 2 3 →